Oncolytics Biotech (ONCY) Competitors $1.08 -0.08 (-6.90%) Closing price 09/4/2025 04:00 PM EasternExtended Trading$1.13 +0.05 (+4.54%) As of 09/4/2025 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ONCY vs. PRTC, INBX, AUTL, KMDA, AURA, YMAB, VIGL, AQST, OLMA, and RCKTShould you be buying Oncolytics Biotech stock or one of its competitors? The main competitors of Oncolytics Biotech include PureTech Health (PRTC), Inhibrx Biosciences (INBX), Autolus Therapeutics (AUTL), Kamada (KMDA), Aura Biosciences (AURA), Y-mAbs Therapeutics (YMAB), Vigil Neuroscience (VIGL), Aquestive Therapeutics (AQST), Olema Pharmaceuticals (OLMA), and Rocket Pharmaceuticals (RCKT). These companies are all part of the "pharmaceutical products" industry. Oncolytics Biotech vs. Its Competitors PureTech Health Inhibrx Biosciences Autolus Therapeutics Kamada Aura Biosciences Y-mAbs Therapeutics Vigil Neuroscience Aquestive Therapeutics Olema Pharmaceuticals Rocket Pharmaceuticals Oncolytics Biotech (NASDAQ:ONCY) and PureTech Health (NASDAQ:PRTC) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, valuation and earnings. Which has more risk & volatility, ONCY or PRTC? Oncolytics Biotech has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500. Comparatively, PureTech Health has a beta of 1.11, suggesting that its share price is 11% more volatile than the S&P 500. Does the media favor ONCY or PRTC? In the previous week, PureTech Health had 1 more articles in the media than Oncolytics Biotech. MarketBeat recorded 2 mentions for PureTech Health and 1 mentions for Oncolytics Biotech. Oncolytics Biotech's average media sentiment score of 0.35 beat PureTech Health's score of 0.11 indicating that Oncolytics Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oncolytics Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PureTech Health 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher earnings & valuation, ONCY or PRTC? PureTech Health has higher revenue and earnings than Oncolytics Biotech. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOncolytics BiotechN/AN/A-$23.14M-$0.27-4.00PureTech Health$4.83M82.72$27.78MN/AN/A Do analysts prefer ONCY or PRTC? Oncolytics Biotech currently has a consensus target price of $5.00, suggesting a potential upside of 362.96%. PureTech Health has a consensus target price of $45.00, suggesting a potential upside of 171.79%. Given Oncolytics Biotech's higher possible upside, equities analysts clearly believe Oncolytics Biotech is more favorable than PureTech Health.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oncolytics Biotech 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80PureTech Health 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Do institutionals and insiders hold more shares of ONCY or PRTC? 6.8% of Oncolytics Biotech shares are owned by institutional investors. Comparatively, 0.0% of PureTech Health shares are owned by institutional investors. 0.1% of Oncolytics Biotech shares are owned by company insiders. Comparatively, 5.3% of PureTech Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Is ONCY or PRTC more profitable? PureTech Health's return on equity of 0.00% beat Oncolytics Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Oncolytics BiotechN/A -438.11% -143.90% PureTech Health N/A N/A N/A SummaryPureTech Health beats Oncolytics Biotech on 8 of the 13 factors compared between the two stocks. Get Oncolytics Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for ONCY and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ONCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ONCY vs. The Competition Export to ExcelMetricOncolytics BiotechMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$116.42M$3.13B$5.76B$9.85BDividend YieldN/A2.28%6.67%4.51%P/E Ratio-4.0020.8975.9926.43Price / SalesN/A458.96546.94119.09Price / CashN/A44.5237.0558.92Price / Book21.609.9310.916.06Net Income-$23.14M-$53.38M$3.29B$266.28M7 Day Performance3.85%0.63%0.18%-0.32%1 Month Performance13.68%6.31%6.26%3.44%1 Year Performance9.31%11.63%51.54%23.11% Oncolytics Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ONCYOncolytics Biotech1.8271 of 5 stars$1.08-6.9%$5.00+363.0%+6.9%$116.42MN/A-4.0030PRTCPureTech Health2.3526 of 5 stars$17.07-1.6%$45.00+163.6%-23.7%$411.93M$4.83M0.00100Short Interest ↑INBXInhibrx Biosciences1.4364 of 5 stars$28.20+1.1%N/A+72.8%$408.49M$200K-2.67166AUTLAutolus Therapeutics3.3669 of 5 stars$1.50-4.5%$9.12+508.0%-64.6%$399.21M$10.12M-1.79330Positive NewsKMDAKamada4.3926 of 5 stars$6.92-1.4%$13.00+87.9%+29.3%$397.93M$160.95M20.35360Positive NewsShort Interest ↑AURAAura Biosciences2.2729 of 5 stars$6.26-2.6%$22.00+251.4%-16.5%$388.87MN/A0.0050YMABY-mAbs Therapeutics3.0495 of 5 stars$8.55+0.1%$9.62+12.5%-40.3%$388.50M$87.68M-17.10150Positive NewsShort Interest ↓VIGLVigil Neuroscience1.4656 of 5 stars$8.05flat$10.80+34.2%N/A$383.91MN/A-3.9340AQSTAquestive Therapeutics1.9839 of 5 stars$3.77-1.6%$10.14+169.0%+19.3%$375.96M$57.56M-5.39160News CoverageAnalyst UpgradeGap UpOLMAOlema Pharmaceuticals2.4801 of 5 stars$5.46-1.1%$24.00+339.6%-44.5%$374.74MN/A-2.7670News CoverageAnalyst ForecastRCKTRocket Pharmaceuticals4.8993 of 5 stars$3.28-2.1%$16.73+410.2%-81.9%$353.92MN/A-1.31240Positive News Related Companies and Tools Related Companies PureTech Health Competitors Inhibrx Biosciences Competitors Autolus Therapeutics Competitors Kamada Competitors Aura Biosciences Competitors Y-mAbs Therapeutics Competitors Vigil Neuroscience Competitors Aquestive Therapeutics Competitors Olema Pharmaceuticals Competitors Rocket Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ONCY) was last updated on 9/5/2025 by MarketBeat.com Staff From Our Partners“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncolytics Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncolytics Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
